{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:06:34Z","timestamp":1782446794024,"version":"3.54.5"},"reference-count":53,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":279,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ES007091"],"award-info":[{"award-number":["ES007091"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ES019487"],"award-info":[{"award-number":["ES019487"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI083927"],"award-info":[{"award-number":["AI083927"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD062489"],"award-info":[{"award-number":["HD062489"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:p>Metformin is an antihyperglycemic drug that is widely prescribed for type 2 diabetes mellitus and is currently being investigated for the treatment of nonalcoholic steatohepatitis (NASH). NASH is known to alter hepatic membrane transporter expression and drug disposition similarly in humans and rodent models of NASH. Metformin is almost exclusively eliminated through the kidney primarily through active secretion mediated by Oct1, Oct2, and Mate1. The purpose of this study was to determine how NASH affects kidney transporter expression and metformin pharmacokinetics. A single oral dose of [14C]metformin was administered to C57BL\/6J (wild type [WT]) and diabetic ob\/ob mice fed either a control diet or a methionine- and choline-deficient (MCD) diet. Metformin plasma concentrations were slightly increased in the WT\/MCD and ob\/control groups, whereas plasma concentrations were 4.8-fold higher in ob\/MCD mice compared with WT\/control. The MCD diet significantly increased plasma half-life and mean residence time and correspondingly decreased oral clearance in both genotypes. These changes in disposition were caused by ob\/ob- and MCD diet\u2013specific decreases in the kidney mRNA expression of Oct2 and Mate1, whereas Oct1 mRNA expression was only decreased in ob\/MCD mice. These results indicate that the diabetic ob\/ob genotype and the MCD disease model alter kidney transporter expression and alter the pharmacokinetics of metformin, potentially increasing the risk of drug toxicity.<\/jats:p>","DOI":"10.2337\/db14-1947","type":"journal-article","created":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T02:01:22Z","timestamp":1432778482000},"page":"3305-3313","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":30,"title":["Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis"],"prefix":"10.2337","volume":"64","author":[{"given":"John D.","family":"Clarke","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika L.","family":"Dzierlenga","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Werts","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Goedken","sequence":"additional","affiliation":[{"name":"Translational Sciences, Research Pathology Services, Rutgers University, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,5,27]]},"reference":[{"key":"2022031300394590100_B1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.5114\/aoms.2012.31622","article-title":"Metformin and its clinical use: new insights for an old drug in clinical practice","volume":"8","author":"Cicero","year":"2012","journal-title":"Arch Med Sci"},{"key":"2022031300394590100_B2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1124\/mol.63.4.844","article-title":"Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin","volume":"63","author":"Wang","year":"2003","journal-title":"Mol Pharmacol"},{"key":"2022031300394590100_B3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2022031300394590100_B4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","article-title":"Clinical pharmacokinetics of metformin","volume":"30","author":"Scheen","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"2022031300394590100_B5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1476-5381.2012.01853.x","article-title":"Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis","volume":"166","author":"Toyama","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2022031300394590100_B6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","article-title":"Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics","volume":"83","author":"Shu","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2022031300394590100_B7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/jpet.102.034140","article-title":"Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin","volume":"302","author":"Wang","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031300394590100_B8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/07853890802552437","article-title":"New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)","volume":"41","author":"Ali","year":"2009","journal-title":"Ann Med"},{"key":"2022031300394590100_B9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2001.25540","article-title":"Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese","volume":"121","author":"Dixon","year":"2001","journal-title":"Gastroenterology"},{"key":"2022031300394590100_B10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000355739","article-title":"Hepatorenal syndrome and novel advances in its management","volume":"37","author":"Fabrizi","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"2022031300394590100_B11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"2022031300394590100_B12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000350158","article-title":"Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography","volume":"37","author":"Mikolasevic","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"2022031300394590100_B13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s11255-014-0796-9","article-title":"Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes","volume":"46","author":"Li","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"2022031300394590100_B14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ajg.2012.06.010","article-title":"Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration","volume":"13","author":"Hamad","year":"2012","journal-title":"Arab J Gastroenterol"},{"key":"2022031300394590100_B15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2010.11.007","article-title":"Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?","volume":"54","author":"Targher","year":"2011","journal-title":"J Hepatol"},{"key":"2022031300394590100_B16","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.metabol.2009.12.012","article-title":"Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis","volume":"59","author":"Yilmaz","year":"2010","journal-title":"Metabolism"},{"key":"2022031300394590100_B17","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.2215\/CJN.05050610","article-title":"Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis","volume":"5","author":"Targher","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031300394590100_B18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2010.07.022","article-title":"Nonalcoholic steatohepatitis and increased risk of chronic kidney disease","volume":"60","author":"Yasui","year":"2011","journal-title":"Metabolism"},{"key":"2022031300394590100_B19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"2022031300394590100_B20","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/dmd.112.044875","article-title":"Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics","volume":"40","author":"Higgins","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"2022031300394590100_B21","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1124\/dmd.110.035006","article-title":"Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease","volume":"38","author":"Hardwick","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2022031300394590100_B22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1681\/ASN.2009121290","article-title":"BTBR Ob\/Ob mutant mice model progressive diabetic nephropathy","volume":"21","author":"Hudkins","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2022031300394590100_B23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2022031300394590100_B24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/dmd.111.041095","article-title":"Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis","volume":"40","author":"Hardwick","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"2022031300394590100_B25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2009.04.002","article-title":"Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats","volume":"613","author":"Fisher","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"2022031300394590100_B26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jhep.2014.02.021","article-title":"Synergistic interaction between genetics and disease on pravastatin disposition","volume":"61","author":"Clarke","year":"2014","journal-title":"J Hepatol"},{"key":"2022031300394590100_B27","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1124\/dmd.111.040592","article-title":"Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease","volume":"39","author":"Lake","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"2022031300394590100_B28","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"2022031300394590100_B29","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"2022031300394590100_B30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1124\/jpet.113.211284","article-title":"Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression","volume":"348","author":"Clarke","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031300394590100_B31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2337\/dc13-2704","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes","volume":"37","author":"Targher","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031300394590100_B32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/FPC.0b013e32834c0010","article-title":"The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c","volume":"21","author":"Christensen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"2022031300394590100_B33","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/mol.109.056242","article-title":"Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin","volume":"75","author":"Tsuda","year":"2009","journal-title":"Mol Pharmacol"},{"key":"2022031300394590100_B34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FPC.0b013e328335639f","article-title":"Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients","volume":"20","author":"Toyama","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"2022031300394590100_B35","doi-asserted-by":"crossref","first-page":"27055","DOI":"10.1074\/jbc.M114.570564","article-title":"Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands","volume":"289","author":"Lee","year":"2014","journal-title":"J Biol Chem"},{"key":"2022031300394590100_B36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/dmd.105.006932","article-title":"Tissue distribution and ontogeny of organic cation transporters in mice","volume":"34","author":"Alnouti","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"2022031300394590100_B37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/FPC.0b013e3283622037","article-title":"Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics","volume":"23","author":"Chung","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"2022031300394590100_B38","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Shu","year":"2007","journal-title":"J Clin Invest"},{"key":"2022031300394590100_B39","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1208\/s12248-013-9460-z","article-title":"Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects","volume":"15","author":"Yoon","year":"2013","journal-title":"AAPS J"},{"key":"2022031300394590100_B40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2337\/db08-1028","article-title":"Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study","volume":"58","author":"Becker","year":"2009","journal-title":"Diabetes"},{"key":"2022031300394590100_B41","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FPC.0b013e328364a57d","article-title":"A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin","volume":"23","author":"Christensen","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"2022031300394590100_B42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40262-013-0046-9","article-title":"Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function","volume":"52","author":"Duong","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2022031300394590100_B43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2022031300394590100_B44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1872-034X.2007.00215.x","article-title":"Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis","volume":"38","author":"de Oliveira","year":"2008","journal-title":"Hepatol Res"},{"key":"2022031300394590100_B45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2008.03723.x","article-title":"Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis","volume":"28","author":"Idilman","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"2022031300394590100_B46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1756283X09105462","article-title":"The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial","volume":"2","author":"Shields","year":"2009","journal-title":"Therap Adv Gastroenterol"},{"key":"2022031300394590100_B47","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"2022031300394590100_B48","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"key":"2022031300394590100_B49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","article-title":"Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial","volume":"20","author":"Nair","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2022031300394590100_B50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(01)06042-1","article-title":"Metformin in non-alcoholic steatohepatitis","volume":"358","author":"Marchesini","year":"2001","journal-title":"Lancet"},{"key":"2022031300394590100_B51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","article-title":"Metformin in the treatment of patients with non-alcoholic steatohepatitis","volume":"19","author":"Uygun","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2022031300394590100_B52","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.gcb.2009.05.010","article-title":"Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial","volume":"33","author":"Sturm","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"2022031300394590100_B53","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/17425255.2014.902444","article-title":"Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease","volume":"10","author":"Scheen","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/64\/9\/3305\/580555\/db141947.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/64\/9\/3305\/580555\/db141947.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T07:08:36Z","timestamp":1717916916000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/64\/9\/3305\/34854\/Mechanism-of-Altered-Metformin-Distribution-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,27]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,5,27]]},"published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db14-1947","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,27]]}}}